Literature DB >> 6452979

Effect of dichloromethane diphosphonate on cortisol-induced bone loss in young adult rabbits.

W S Jee, H E Black, J E Gotcher.   

Abstract

Cortisol, 2.5 mg/kg, dichloromethane diphosphonate (Cl2MDP), 0.1, 1.0 and 4.0 mg/kg, and combinations of the two were administered daily for 42 days to young adult rabbits (3.9 kg) to determine if Cl2MDP could inhibit development of cortisol-induced osteopenia. A beginning and a terminal control group were included in the experiment. In the terminal controls compared with the beginning controls, the proximal tibia lost cortical and trabecular bone, the distal femur gained cortical bone and the lumbar vertebral body lost trabecular bone. The administration of Cl2MDP alone inhibited bone resorption at those sites where bone loss was occurring. Two cortical bone sites showed gains in bone. The 1.0 mg/kg dose was most effective. In rabbits administered cortisol, bone formation was inhibited; the number of osteoclasts was markedly increased, cortical bone was lost in all the bones examined, and there was no marked effect on trabecular bone. Cl2MDP administered with cortisol partially inhibited cortisol-induced bone loss. The concomitant administration of Cl2MDP did not alter the number of osteoclasts and osteoblasts. The 1.0 mg/kg dose was most effective. The results of this study clearly demonstrated the need to evaluate several bones and different sites within individual bones if erroneous conclusions are to be avoided when studying agents that affect bone metabolism.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6452979

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  9 in total

Review 1.  [Introduction to bisphosphonates. History and functional mechanisms].

Authors:  H Fleisch
Journal:  Orthopade       Date:  2007-02       Impact factor: 1.087

2.  Comments on "cyclosporin does not affect the absolute rate of cortical bone resorption at the organ level in the growing rat".

Authors:  S Epstein; W S Jee; Y Ma; C C Liu
Journal:  Calcif Tissue Int       Date:  1995-06       Impact factor: 4.333

Review 3.  Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.

Authors:  H Fleisch
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

4.  The ADFR concept revisited.

Authors:  H M Frost
Journal:  Calcif Tissue Int       Date:  1984-07       Impact factor: 4.333

Review 5.  Rationale for the use of alendronate in osteoporosis.

Authors:  J A Kanis; B J Gertz; F Singer; S Ortolani
Journal:  Osteoporos Int       Date:  1995-01       Impact factor: 4.507

Review 6.  New bisphosphonates in osteoporosis.

Authors:  H Fleisch
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

7.  Effects of glucocorticoids on skeletal growth in rabbits evaluated by dual-photon absorptiometry, microscopic connectivity and vertebral compressive strength.

Authors:  B Grardel; B Sutter; B Flautre; E Viguier; F Lavaste; P Hardouin
Journal:  Osteoporos Int       Date:  1994-07       Impact factor: 4.507

Review 8.  Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  G L Plosker; K L Goa
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

Review 9.  Drugs in development: bisphosphonates and metalloproteinase inhibitors.

Authors:  Jon B Catterall; Tim E Cawston
Journal:  Arthritis Res Ther       Date:  2002-11-08       Impact factor: 5.156

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.